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Background. The human immunodeficiency virus (HIV) fuels tuberculosis (TB) epidemics. In controlled clinical trials,
antiretroviral therapy (ART) reduces TB incidence in HIV-infected patients. In this study we determine if, under programmatic
conditions, Brazil’s policy of universal ART access has impacted TB incidence among HIV-infected patients. Methods. We
abstracted clinical information from records of HIV-infected patients managed in the public sector in 11 Brazilian states
between 1/1/1995 and 12/31/2001. Case ascertainment (TB and HIV) utilized guidelines (with added stringency) published by
Brazil’s Ministry of Health. We determined TB incidence and hazards ratio (HR) for ART-naı¨ve and ART-treated [including highly
active ART (HAART)] patients employing Cox proportional hazards analysis. Results. Information from 463 HIV-infected
patients met study criteria. The median age of the study population was 34 years, 70% were male, and mean follow-up to
primary endpoints—TB, death, and last clinic visit—was 330, 1059, and 1125 days, respectively. Of the 463 patients, 76 (16%)
remained ART-naı¨ve. Of the patients who never received HAART (n = 157) 81 were treated with ART non-HAART. Of the patients
who received any ART (n = 387), 306 were treated with HAART (includes those patients who later switched from ART non-
HAART to HAART). Tuberculosis developed in 39/463 (8%) patients. Compared to HAART- and ART non-HAART-treated patient
groups, TB incidence was 10- (p,0.001) and 2.5-fold (p = 0.03) higher in ART-naı¨ve patients, respectively. The median baseline
absolute CD4+ T-lymphocyte count for patients who developed TB was not significantly different from that of patients who
remained TB free. In multivariate analysis, the incidence of TB was statistically significantly lower in HAART-treated [HR 0.2;
95% (CI 0.1, 0.6); p,0.01] compared to ART naı¨ve patients. A baseline CD4+ T-lymphocyte count ,200 cells/mm3 [HR 2.5; (95%
CI 1.2, 5.4); p,0.01], prior hospitalization [HR 4.2; (95% CI 2.0, 8.8); p,0.001], prior incarceration [HR 4.1; 95% CI 1.6, 10.3);
p,0.01], and a positive tuberculin skin test [HR 3.1; (95% CI 1.1, 9.0); p = 0.04] were independently and positively associated
with incident TB. Conclusion. In this population-based study we demonstrate an 80% reduction in incident TB, under
programmatic conditions, in HAART-treated HIV-infected patients compared to ART-naı¨ve patients.
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INTRODUCTION
Tuberculosis (TB) is the leading cause of morbidity and mortality
in people living with the human immunodeficiency virus (HIV) [1–
4]. Patients infected with HIV are at increased risk, up to 10% per
year, of reactivating latent Mycobacterium tuberculosis infection, and
of accelerated progression to TB disease soon after infection [5–8].
In addition, HIV appears to increase the rate of TB re-infection
and recurrent disease [9,10]. During the last decade, TB case
notification rates have risen sharply in areas of high HIV
prevalence, such as sub-Saharan Africa, largely attributable to
the HIV epidemic [8,11–13]. The World Health Organization
(WHO) recommends that affected countries implement collabo-
rative programmatic TB/HIV activities, including antiretroviral
therapy (ART), as part of the health sector response to this
syndemic [14,15].
Before 1996, ART consisted of an antiretroviral (ARV) agent
(primarily a nucleoside reverse transcriptase inhibitor, or NRTI)
given alone or in combination with another ARV agent.
Thereafter, the introduction of highly active ART (HAART),
consisting of three ARV agents [including NRTI, non-nucleoside
transcriptase inhibitors (NNRTI) and protease inhibitors (PI)], has
had a significant impact on reducing the incidence of opportunistic
infections (OI) in HIV-infected patients [16–19]. In prospective
clinical studies, HAART has been shown to reduce the incidence
of TB by as much as 80% [20–23]. Further, epidemiological
models of TB in a theoretical setting of ART accessibility have
demonstrated considerable impact of HAART on TB incidence,
but these estimates have relied on assumptions such as ART being
initiated early in the course of HIV infection and very high levels
of treatment adherence being attained [24]. The true impact of
ART on TB among people living with the human immunodefi-
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ciency virus under normal program conditions, however, has not
been previously reported.
In 1996, Brazilian federal law established a mandate granting
universal access to ART for all eligible HIV-infected individuals
[25]. In a nation where the high national TB burden [estimated
(2005) all case TB incidence and prevalence of 60/100,00
population (pop)/yr and 76/100,000 pop, respectively] points to
significant community transmission, where the adult (15–49 yrs)
HIV prevalence (2005) among TB patients is 14%, and where the
vast majority of TB and HIV patients are managed in the public
sector, Brazil’s public policy guaranteeing universal ART access
has important implications for TB control [25]. According to the
WHO, in 2005, 9529 new TB cases and 2281 TB deaths (all
forms) were attributable to HIV, despite the fact that 86% of
known HIV-infected adults eligible for ART in Brazil were
receiving this therapy [26,27]. However, up to 64% of prevalent
HIV infections remain undiagnosed in the country, according to
estimates (2002) by Brazil’s Ministry of Health (MoH), Programa
Nacional de DST e AIDS (national program for STI and AIDS—
unpublished data). This estimate suggests that, in addition to the
need for improved HIV counseling and testing access, the total
burden of HIV infection in Brazil represents a large reservoir of
people at increased risk of TB [20–23].
This population-based study sought to evaluate the impact of
universal access to ART on TB disease incidence in HIV-infected
patients managed in the public health sector in Brazil.
METHODS
Study population
The study population comprised a retrospective cohort of HIV-
infected individuals receiving care in public HIV treatment
facilities in Brazil.
The study sample size, 474, was calculated to discern
a minimum protective effect of 35% among HAART-treated
compared to ART-naı¨ve patients with a 95% confidence level and
80% statistical power [28]. In 2000, 11% of all new TB cases in
adults, globally, occurred in persons infected with HIV; and we
used this figure to estimate the frequency of TB among ART-naı¨ve
HIV-infected individuals in our sample size calculation [13]. The
study population was drawn from systematically selected public
HIV treatment facilities in Brazil using population-proportional-
to-size sampling, cluster size of 20 patients, and selection of records
at facilities by generating random number lists.
Inclusion Criteria
The medical records of patients were abstracted if (a) the initial
facility visit was recorded to be between January 1, 1995 and
December 31, 2001, and (b) HIV was diagnosed and confirmed
during that period. Only an HIV Western Blot, indirect
immunofluorescence testing, or evidence of viremia (by poly-
merase chain reaction) were accepted as confirming the diagnosis.
Medical records of patients were excluded if there was evidence
that the patient had attended clinic only once during the study
period, were ,18 years of age, pregnant, or wards of the state.
Data abstraction
Data abstractors, trained by investigators, utilized standardized and
validated data collection tools to transcribe information from patient
records. Information collected included patient demographics;
historical information about TB, incarceration, hospitalization,
injection drug use (IDU), and homelessness; presumptive HIV
transmission route; date of and vital status at last recorded facility
visit; HIV-related diseases included in the WHO clinical staging
system [29]; baseline and follow-up CD4+ T-lymphocyte counts and
plasma viral load; tuberculin skin testing (TST) and acid-fast bacilli
(AFB) smear and culture results; diagnostic x-ray and pathology
reports; and, if administered, date and duration of prescribed ART,
TB treatment, co-trimoxazole (CTM) prophylactic treatment, and
isoniazid preventive therapy (IPT).
Antiretroviral therapy
According to the Brazil national HIV clinical guidelines, in brief,
all patients, regardless of symptomatology, are eligible for ART if
their CD4+ T-lymphocyte count (in Brazil determined by flow
cytometry) is ,200 cells/mm3; or if patients develop HIV-
associated clinical manifestations such as Pneumocystis jiroveci (carinii)
pneumonia [25,30]. Antiretroviral therapy is considered in
asymptomatic patients with CD4+ T-lymphocyte counts between
200 and 350 cells/mm3 according to the clinical and laboratory
evolution of their immunological features (e.g., presence of OI and
measured plasma viral load) and patient characteristics (e.g.,
adherence and motivation) [30].
The ARV agents and ART regimens received by patients
between the initial facility visit and a study primary endpoint (see
below) are listed in Tables 1 and 2. We classified ART as, (1)
HAART: a combination of (a) 2 NRTI+1 PI, or (b) 2 NRTI+1
NNRTI, or (c) 1 NRTI+1 NNRTI+1 PI; (2) ART non-HAART:
any single ARV agent or combination not defined as HAART;
and (3) ART-naı¨ve: no ART received.
Tuberculosis case definition
We classified a case of TB based on a modified (i.e., more
stringent) case definition as published in the Brazil national TB
guidelines as, (a) confirmed: Mycobacterium tuberculosis isolated in
culture from a clinical specimen, (b) probable: AFB identified by
Kinyoun or Ziehl-Neelsen staining in a clinical specimen, and (c)
presumed: documented evidence of an abnormal chest x-ray
consistent with TB disease, caseous granulomatous reaction in
a tissue specimen, or the prescription of anti-TB treatment by
a physician [31]. Pulmonary TB was defined as TB disease
involving the lungs, irrespective of whether disease was present in
other locations; whereas extrapulmonary TB was defined as TB
disease excluding the lungs.
CD4+ T-lymphocyte count
A baseline CD4+ T-lymphocyte count was defined as the result of
this test at initial facility visit; whereas, the pre-diagnostic CD4+
Table 1. Cumulative list of antiretroviral agents available in
public HIV treatment facilities in Brazil between January 1,
1995 and December 31, 2001.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NRTI* NNRTI** Protease inhibitors
Abacavir Delavirdine Amprenavir
Didanosine Efavirenz Atazanavir
Lamivudine Nevirapine Indinavir
Stavudine Lopinavir/ritonavir
Zalcitabine Nelfinavir
Zidovudine Ritonavir
Zidovudine/Lamivudine Saquinavir
*Nucleoside reverse transcriptase inhibitor
**Non-nucleoside reverse transcriptase inhibitor
doi:10.1371/journal.pone.0000826.t001..
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T-lymphocyte count was defined as the result of the test closest to
the time of TB diagnosis.
Data analysis
Data analysis was performed using Epi Info v.6 and v.3.1 (CDC,
Atlanta, GA, USA) and SAS v.8.01 (SAS Institute, Cary, NC, USA).
Observations were censored at the date of TB diagnosis, date of last
clinic visit, date of patient death, or January 1, 2002 (i.e., primary
endpoints). We excluded from analysis patients in whom TB was
diagnosed within 30 days of the recorded initial clinic visit because
the immunorestorative effect of ART [we used the immune
reconstitution syndrome (IRIS) as a marker for this] would not be
expected to develop in most HIV-infected TB patients within the
first 4 weeks (range 0 to12 weeks) of initiating ART [32,33].
Cox proportional hazards modeling was used to calculate
hazards ratios, 95% confidence limits, and p-values in univariate
screening and multivariate analysis. Variables associated with a
p-value#0.2 in univariate screening were considered for the
multivariate model. In the univariate screening, patients whose
treatment was switched from ART non-HAART to HAART
during the study period were considered in the HAART group
irrespective of the amount of time they would eventually spend on
HAART. In multivariate analysis, the proportional amount of
time on ART non-HAART and HAART were treated as time-
dependent co-variables. All two-way interactions were tested.
Manual backward stepwise regression was used to construct the
final model. A p-value#0.05 was considered statistically signifi-
cant.
Ethical considerations
The protocol for this study was approved by Brazil’s MoH ethical
review committee and determined as non-research by the National
Center for HIV, STD, and TB Prevention of the US Centers for
Disease Control and Prevention. Patient medical records kept at
facilities contained routinely-collected clinical information and
only this information was obtained. The study included no patient
contact, and the abstraction forms and databases created for this
study recorded no patient identifiers. Data abstractors were
trained in issues of confidentiality and privacy by investigators.
RESULTS
Of 1002 records reviewed in 29 facilities in 11 Brazilian states, 307
(31%) were not included because 203/307 (66%), 63/307 (21%),
and 41/307 (13%) individuals were not HIV-infected, lacked an
HIV confirmatory test, and their initial facility visit occurred
outside of the date parameters for inclusion, respectively. Of the
remaining 695 (69%) records, 174 (25%) met exclusion criteria
[73/174 (42%), 57/174 (33%), 12/174 (7%), and 32/174 (18%)
represented individuals who attended clinic only once, were
pregnant, were ,18 years of age, or met more than one exclusion
criteria, respectively]. An additional 58/695 (8%) records were
excluded due to a recorded TB diagnosis occurring within 30 days
of the recorded initial facility visit. Thus, 463/695 (66%) records
comprised the study population, the median age of which was
34 years (range 18–71), and 70% were male (Table 3).
Except for patients with a history of injection drug use (IDU;
X2, p = 0.02), no statistically significant differences were observed
between the patients who eventually developed TB and those who
did not develop TB with respect to sex, age, mode of sexual
transmission, or state where the patient was clinically managed
(Table 3). For whom the information was available in the patient
record (i.e., denominators vary), 229 and 116 of 379 patients
presented with a baseline viral load of $10,000 and $100,000
copies/ml, respectively; and 263/429 (61%) presented with
a baseline CD4+ T-lymphocyte ,200 cells/mm3. Two-hundred
and twenty-three of 271 (82%) patients presented or developed
WHO stages 3 or 4 clinical disease. Recorded modes of HIV
transmission (not mutually exclusive) included 136/232 men who
had sex with men (MSM), 61/461 with history of IDU, 232/297
with multiple sexual partners (heterosexual and MSM), 151/244
with HIV-positive partner contact, and 12/331 with prior blood
transfusion.
Except for the 76/463 (17%) patients who remained ART-
naı¨ve, all patients who initiated any ART (n = 387) did so at some
point after their initial recorded facility visit. At the time of the
primary endpoints, 245 [patients treated exclusively with ART
non-HAART (n = 81)+those initially treated with ART non-
HAART and later switched to HAART (n = 164)] and 306
[patients treated exclusively with HAART (n = 142)+those initially
treated with ART non-HAART and later switched to HAART
(n = 164)] patients had contributed survival time to ART non-
HAART and HAART regimens, respectively (Fig. 1). One
hundred-fifty seven patients received no HAART. The drug
classes and specific agents that composed the most commonly
Table 2. List of the most commonly prescribed classes of and
specific antiretroviral agents and their combinations used in
HAART and ART non-HAART ART regimens among patients
attending public HIV treatment facilities in Brazil (n = 463)
between January 1, 1995 and December 31, 2001.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Most commonly prescribed ART regimens
No. of times used, at least
once, during the study period
HAART
Drug classes*: NRTI**62+PI***61 221
NRTI62+NNRTI**61 119
Specific^
zidovudine+lamivudine+indinavir 81
zidovudine+lamivudine+nelfinavir 49
zidovudine+lamivudine+nevirapine 46
stavudine+lamivudine+indinavir 29
zidovudine+didanosine+indinavir 25
zidovudine+lamivudine+efavirenz 24
ART non-HAART
Drug classes: NRTI62 208
NRTI61 61
Specific:
zidovudine+didanosine 133
zidovudine 51
zidovudine+lamivudine 51
zidovudine+zalcitabine 48
stavudine+lamivudine 17
didanosine+stavudine 11
*A total of 36 unspecified ART regimens (HAART = 22 and ART non-HAART = 14)
were cumulatively used for at least one day, 780 times during the study
period,
**See footnotes, Table 1
***Protease inhibitors (includes ritonavir-boosted regimens)
^A total of 177 specific ART regimens were cumulatively used for at least one
day, 1421 times during the study period,
,Note that the number of ART regimens cumulatively used during the study
period exceeds the total study population because, for those on ART, more
than one regimen may have been prescribed during the study period
doi:10.1371/journal.pone.0000826.t002..
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prescribed ART regimens in this study are listed in Table 2. At
least one dose of CTM was prescribed for 204/441 (46%) patients.
Nine (23%) confirmed, 8 (21%) probable, and 22 (56%)
presumed TB diagnoses (n = 39) were made during the study
period. Twenty-three (59%) patients had pulmonary TB, the
remaining 16 (41%) had extrapulmonary disease. Eighteen (46%)
TB cases occurred in ART-naı¨ve patients. The median baseline
absolute CD4+ T-lymphocyte count for patients who developed
TB was not significantly different from patients who remained TB
free (111 cells/mm3 vs. 253 cells/mm3, respectively. X2, p.0.05).
However, a higher proportion of patients with TB had median
baseline CD4+ T-lymphocyte counts ,200 cells/mm3 compared
to patients without TB (57% vs. 37%, respectively. X2, p = 0.01).
The median pre-diagnostic (TB) CD4+ T-lymphocyte count was
134 cells/mm3 (range 6–821 cells/mm3). The median time elapsed
between the pre-diagnostic CD4+ T-lymphocyte count and the
diagnosis of TB was 73 days (range 0–572).
Mean duration of follow-up from the initial recorded facility
visit to a primary endpoint was 330, 1059, and 1125 days for TB
diagnosis , patient death, and last clinic visit, respectively. Of the
43 (9% of study population) patient deaths recorded during the
study period, 3 had been diagnosed with TB disease (X2: p.0.05).
We analyzed potential risk factors for TB disease in the study
population (Table 4). Patients with a baseline CD4+ T-lymphocyte
count of ,200 cells/mm3 had more than twice the incidence of TB
disease than those with a baseline CD4+ T-lymphocyte count.200
cells/mm3 {hazards ratio (HR) 2.3; [95% confidence interval (CI)]
1.2, 4.4}. A history of IDU, incarceration, hospitalization, and prior
TB were also associated with a statistically significantly higher
incidence of TB disease (Table 4). No statistically significant
difference was observed in the incidence of TB disease among
patients with baseline (i.e., at initial visit to the facility) WHO clinical
stages 3 and 4 vs. 1 and 2, [HR 1.4; (95% CI 0.5, 3.6)].
In univariate screening (Table 4), ART-naı¨ve patients had
a statistically significantly higher incidence of TB disease than
those receiving any ART [HR 5.0; (95% CI 3.3, 10.0); p,0.01].
Statistically significant protective effects against incident TB
disease was observed for both ART non-HAART (exclusively)
[HR 0.4; (95% CI 0.2, 0.9), p = 0.03] and HAART [HR 0.1; (95%
CI, 0.1, 0.2), p,0.001].
In multivariate analysis, controlling for type of ART intervention,
a baseline CD4+ T-lymphocyte count ,200 cells/mm3, IPT, and
prior history of TB, hospitalization, incarceration and IDU (Table 5),
only HAART (vs. ART naı¨ve) was associated with a statistically
significant reduction in TB disease incidence [HR 0.2 (95% CI 0.1,
0. 6); p,0.01]. The reduction in TB disease among patients
receiving ART non-HAART (vs. ART naı¨ve) did not reach
statistical significance [HR 0.4; (95% CI 0.2, 1.1); p = 0.08]. A
baseline CD4+ T-lymphocyte count ,200 cells/mm3 [HR 2.5;
(95% CI 1.2, 5.4); p,0.01], prior hospitalization [HR 4.2; (95% CI
2.0, 8.8); p,0.001] , prior incarceration [HR 4.1; 95% CI 1.6, 10.3);
p,0.01], and a positive tuberculin skin test [HR 3.1; (95% 1.1, 9.0);
p = 0.04] were independently and positively associated with incident
TB. All two-way interaction terms were tested and none were found
to be statistically significant (i.e., p.0.1).
Ninety-five percent, 86%, and 69% of patients who received
HAART, ART non-HAART , and remaining ART naı¨ve,
respectively, remained free of TB disease at primary endpoints
(p,0.001 for all three situations, when evaluated together; see
Figure 2).
Table 3. Socio-demographic characteristics, by TB status, of patients attending public HIV treatment facilities in Brazil (n = 463)
between January 1, 1995 and December 31, 2001.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristic Number with feature/total* (%) No. with TB (%) p-value
Sex Male 322/459 (70) 30 (9)
Female 137 (30) 9 (6) NS
Age groups (years) 18–29 128/452 (28) 13 (10)
Median age 34 years 30–34 113 (25) 8 (7) NS
(range 18–72 years) .34 211 (47) 18 (9)
State where patient treated Bahia (BA) 16/463 (3) 1 (6)
Goias (GO) 36 (8) 2 (6)
Minas Gerais (MG) 16 (3) 2 (6)
Mato Grosso do Sul (MS) 17 (4) 0 (0)
Pernambuco (PE) 13 (3) 0 (0)
Parana (PR) 12 (3) 1 (8) NS
Rio de Janeiro (RJ) 62 (13) 6 (10)
Rio Grande do Norte (RN) 15 (3) 1 (7)
Rio Grande do Sul (RS) 17 (4) 1 (6)
Santa Catarina (SC) 13 (3) 3 (23)
Sa˜o Paulo (SP) 246 (53) 22 (9)
Mode transmission Ever injection drug
Use (IDU) 61/461 (13) 10 (16) 0.02
Heterosexual** 107/232 (46) 10 (9) NS
Male sex with male** 136 (59) 12 (9) NS
*Denominators vary due to missing data in the patient medical record for each characteristic (missing values deleted from analysis)
**Each subcategory (i.e., heterosexual and MSM) includes the subset of male patients who were reported as bisexual (n = 45 of 152 heterosexual males), and therefore,
the sum of the numerators of both subcategories is greater than the denominator
doi:10.1371/journal.pone.0000826.t003..
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The mortality rate of the study population at study end was 0.24
per 100-person years of follow-up. The proportional mortality of
severely immunocompromised TB patients (CD4+ T-lympho-
cyte,200 cells/mm3) at 6 and 12 months after starting TB
treatment, was 0.8% and 1.1%, respectively.
DISCUSSION
In this population-based retrospective cohort analysis of adult
HIV-infected patients managed under normal programmatic
conditions in public HIV treatment facilities in Brazil, we observed
a statistically significantly lower (80%, p,0.01) incidence of TB in
patients prescribed HAART compared to patients who remained
ART-naı¨ve. This effect of HAART remained statistically signif-
icant even when controlling for the patients’ baseline immuno-
logical status, and other important characteristics and interven-
tions (Tables 4 and 5). Though treatment with ART non-HAART
also resulted in a lower TB incidence rate, the reduction did not
reach statistical significance (p = 0.08). The findings in this study
serve to validate similar findings in previous, more controlled
studies, and demonstrate that it is possible for national programs to
provide access to HAART under ‘‘real world’’ conditions, and in
doing so, reduce the risk of the most common OI of adults living
with HIV—TB [19–22].
In Brazil, it is customary for HIV treatment facilities to take
over the care of newly diagnosed HIV-infected patients in the
public sector, and thereafter, provide longitudinal comprehensive
clinical management and ART, as indicated [25]. According to
the WHO, 86% of diagnosed and eligible HIV-infected patients in
Brazil were receiving ART in 2004, a proportion superior to that
of low and middle income countries (e.g., Peru, 18%); and similar
to that of developed countries in South America such as Argentina
and Chile (both 100%) [26]. However, while access to ART
remains very important, a significant impact in the reduction TB
incidence for people living with HIV is unlikely unless a large
proportion of the subset who are unaware of their HIV serostatus
are tested, and national programs are able to deliver high quality
comprehensive clinical care, including effective provision of ART
to this population.
The patients who developed TB disease in our study had similar
risk factors for TB as HIV-infected patients in other settings, and
Figure 1. Breakdown of study patients attending public HIV treatment facilities in Brazil (n = 463) between January 1, 1995 and December 31,
2001 by intervention (HAART, ART non-HAART), and non-intervention (ART naı¨ve).
doi:10.1371/journal.pone.0000826.g001
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Table 4. Univariate Cox proportional hazards screening of risk of TB among patients attending public HIV treatment facilities in
Brazil (n = 463) between January 1, 1995 and December 31, 2001.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristic*,ˆ
No. with feature/
Total^^ (%)
No. with
TB#
TB Incidence
per 100 person-years
Hazard ratio
(95% CI) p-value
Antiretroviral therapy Any ART 387/463 (84) 21 1.9 0.2 (0.1, 0.3) ,0.01
ART-naı¨ve 76 (16) 18 13.4
ART non-HAART exclusively 81/157 (52) 10 4.9 0.4 (0.2, 0.9) 0.03
ART-naı¨ve 76 (48) 18 13.4
HAART 306/387 (80) 11 1.2 0.1 (0.1, 0.2) ,0.001
ART-naı¨ve 76 (20) 18 13.4
HAART 306/387 (79) 11 1.2 0.3 (0.1, 0.6) ,0.01
ART non-HAART exclusively 81 (21) 10 4.9
Baseline WHO clinical stage 3 or 4 223/271 (82) 29 5.0 1.4 (0.5, 3.6) NS
1 or 2 48 (12) 5 3.4
Baseline CD4+ T-lymphocyte count
(cells/mm3)
$200 166/429 (39) 21 2.0 2.3 (1.2, 4.4) 0.01
,200 263 (61) 16 5.1
$350 283/429 (66) 8 1.8 2.0 (0.9, 4.4) NS
,350 146 (34) 29 3.6
Baseline HIV serum viral load
(copies/ml)
$10,000 229/379 (60) 12 2.7 1.0 (0.5, 2.2) NS
,10,000 150 (40) 18 2.7
$100,000 116/379 (31) 12 3.9 1.7 (0.8, 3.5) NS
,100,000 263 (69) 18 2.3
Co-trimoxazole prophylactic
treatment
Yes 204/441 (46) 13 2.5 0.6 (0.3, 1.2) NS
No 237 (54) 26 3.9
Tuberculin skin test positive (TST+) Positive 21/122 (19) 4 7.0 3.0 (0.9, 10.7) NS
Negative 101 (81) 6 2.1
Isoniazid preventive Treatment
(in TST+)
Yes 11/21 (52) 0 5.5 0.0 (0.0, -) 0.06
No 10 (48) 3 12.0
Prior history of TB Yes 30/397(8) 25 11.9 4.0 (1.7, 9.2) ,0.01
No 367 (92) 7 3.0
Prior contact with TB patient Yes 15/113 (13) 2 6.0 7.1 (1.0, 50.3) NS
No 98 (87) 2 0.7
History of ever having been
hospitalized
Yes 163/409 (40) 27 7.0 5.1 (2.4, 10.9) ,0.001
No 246 (60) 9 1.3
History of ever having been
incarcerated
Yes 18/245 (7) 6 16.8 5.0 (2.0,12.4) ,0.001
No 227 (93) 26 3.3
Ever homeless Yes 10/279 (4) 2 13.7 4.5 (1.0, 19.3) NS
No 269 (96) 19 2.7
Ever IDU Yes 61/461 (13) 10 6.4 2.5 (1.2, 5.1) 0.01
No 400 (87) 29 2.6
*Denominators vary due to missing data from the patient medical record for characteristic (missing values deleted from analysis)
^Reference value appears bolded on the second line of each characteristic. Note that those patients who received ART non-HAART and were later switched to HAART
were classified as patients having received HAART (see data analysis section of Methods)
^^The word ’’Total’’ in the ‘‘No. with feature/Total’’ column refers to the denominator for each particular characteristic (e.g., 81 out of a total of 157 patients who did not
receive HAART were treated with ART non-HAART exclusively)
#The total number of patients who developed TB (n = 39) varies for each characteristic according to whether or not patients were excluded from analysis due to
incomplete information (in the patients’ medical record) for that characteristic
doi:10.1371/journal.pone.0000826.t004..
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66% eventually received HAART [1,8,11,22,34,35]. Nevertheless,
11 (4%) patients developed TB disease despite receiving HAART.
A higher proportion of patients with TB had median baseline
CD4+ T-lymphocyte counts ,200 cells/mm3 compared to
patients without TB (57% vs. 37%, respectively. X2, p = 0.01).
This suggests that those who developed TB may have been more
immunocompromised at baseline than patients remaining TB free;
however, the median baseline absolute CD4+ T-lymphocyte count
and baseline WHO clinical staging characteristics were not
significantly different between the two groups. We cannot exclude
the possibility, however, that the study lacked the power to detect
subtle but clinically important immunological differences among
groups. In areas of high TB prevalence, TB can occur at all levels
of CD4+ T-lymphocyte count, though ART-naı¨ve patients who
develop TB frequently present with low CD4+ T-lymphocyte
counts prior to TB diagnosis [36,37]. Both HAART and non-
HAART regimens have been shown to raise CD4+ T-lymphocyte
counts and improve the clinical status of HIV-infected patients
with and without concomitant OI [20,38,39]. This suggests that
other factors may be affecting TB disease risk after initiating ART.
Indeed, evidence exists to suggest that HAART is unable to fully
restore the immune response to Mycobacterium tuberculosis in HIV-
infected patients, leading to a chronically heightened TB risk over
an increased lifespan [39–41]. Addressing this heightened risk
poses a challenge for the future control of TB; however, growing
evidence also suggests that this risk may be mitigated by early
initiation of HAART with corresponding high levels of treatment
adherence [24,41,42]. Fortunately, currently and widely recom-
mended clinical guidelines for the treatment of HIV infection and
TB disease are helping to eliminate an important negative factor
from the TB/HIV equation—suboptimal ART. Because of the
timeframe selected for this study, 1995–2001, it was not
Table 5. Adjusted* hazards ratio of the risk of tuberculosis
among patients attending public HIV treatment facilities in
Brazil (n = 463) between January 1, 1995 and December 31,
2001 in a Cox proportional hazards model.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristic
Adjusted hazards ratio
for TB disease (95% CI) p-value
HAART (vs. ART-naı¨ve) 0.2 (0.1, 0. 6) ,0.01
ART non-HAART exclusively (vs. ART-
naı¨ve)
0.4 (0.2, 1.1) 0.08
Baseline CD4+ T-lymphocyte count
,200 cells/mm3
2.5 (1.2, 5.4) ,0.01
Tuberculin skin test positive 3.1 (1.1, 9.0) 0.04
History of ever having been hospitalized 4.2 (2.0, 8.8) ,0.001
History of ever having been incarcerated 4.1 (1.6, 10.3) ,0.01
*All two-way interactions were tested
Note: neither the term co-trimoxazole prophylactic treatment nor IPT were
statistically significant in the final model
doi:10.1371/journal.pone.0000826.t005..
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Figure 2. Kaplan-Meier survival curve* of the proportion of patients attending public HIV treatment facilities in Brazil (n = 463) between January
1, 1995 and December 31, 2001 who remained TB free at primary study endpoint (i.e., TB, death, or last clinic visit) over the time course (in
days) of the study period, by intervention (HAART, ART non-HAART), and non-intervention (ART naı¨ve).
doi:10.1371/journal.pone.0000826.g002
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uncommon, early within this time interval, to document ART
regimens consisting of single and dual ARV agents. Nevertheless, we
saw a corresponding shift toward HAART (data not shown) in this
study as scientific thought about ART gradually evolved after 1995
[41]. Attention to other factors such as facility infection-control,
active case finding, and wider use of appropriately administered IPT
could be instrumental in further reducing TB disease risk in HIV-
infected individuals (Golub JE, et al. Tuberculosis incidence by
HAART and isoniazid prophylactic therapy in HIV-infected
patients in Rio de Janeiro, Brazil. XVI International AIDS
Conference, 2006 Abstract no. MoPE0395) [5,9,23,42–45]. On-
going studies with regard to the use of IPT in HIV infection should
elucidate the optimal use of this intervention (Samandari T, et al.
Characteristics of people living with HIV-1 screened for isoniazid
preventive therapy-Botswana, 2004–2005. AIDS 2006-XVI In-
ternational AIDS Conference, 2006 Abstract no. MoAB010).
Finally, there is now reliable information showing that HIV-
related morbidity and mortality in adults and children, including
that due to TB disease co-morbidity, can be significantly reduced
with the adjunctive use of CTM prophylaxis [46–48]. We found
that the mortality rate and overall mortality of the cohort and of
severely immunocompromised TB patients was comparable, if not
lower, than that observed for HIV infected patients managed and
reported in high income countries after 1995 [16,17,49]. And,
while many factors clearly confound any mortality considerations
in this study, the fact that 46% and 33% of the cohort and of TB
patients, respectively, in the study received at least one dose of
CTM probably contributed to favorable outcomes in these
patients. As is probably the case in many other clinical settings
globally, the use of CTM prophylaxis among HIV-infected
populations with TB can clearly be improved and, in doing so,
independently reduce patient morbidity and mortality.
Our study population specifically excludes children (age,18 -
years) and pregnant women. Due to the retrospective and
observational design of this study, we were also unable to control
for factors specific to (a) patients (e.g., adverse nutritional and
psycho-social issues); (b) facilities (e.g., infection control measures);
and, (c) programs [e.g., erratic pharmacy drug stocks and diagnostic
rigor (e.g., low sensitivity and specificity of X-ray imaging)]. In
addition, patients with only one clinic visit were explicitly excluded
from the study, and we were unable to consistently determine the
degree of patient adherence to therapeutic regimens from patient
records. With regards to treatment adherence, however, WHO and
others estimate adherence to be approximately 75% among patients
on ART in Brazil [27,50].
An additional limitation of our study was that the majority of
the TB diagnoses recorded were made, primarily, on clinical
grounds (i.e., presumed); and therefore, an alternative diagnosis to
TB cannot be excluded. As the most common opportunistic
disease of HIV-infected patients, however, the clinical experience
of health care staff in facilities with large HIV patient populations
probably lessens this possibility. In addition, TB misdiagnosis
would only tend to underestimate the degree of TB incidence
reduction by HAART.
Despite the limitations of the study and the fact that a proportion
of study patients received sub-optimal ART before being switched
to HAART, the significant reduction in TB disease observed is all
the more remarkable. Our findings, however, are not applicable to
pediatric patients, and should be interpreted in light of the study
limitations.
We conclude that, in settings of unrestricted access to ART,
HAART can have a significant impact on the TB incidence of HIV-
infected patients developing. We found that, even under pro-
grammatic conditions, a statistically significant reduction in TB
incidence of 80% was observed among HIV-infected patients
receiving HAART in the public sector in Brazil compared to patients
who remained ART-naı¨ve. We demonstrate that, although broad
access to ART remains an elusive goal of low and middle income
countries, a national policy that drives the effective implementation
of a program that manages HIV-infected patients using HAART is
an initiative that is not only beneficial in reducing TB disease in
HIV-infected patients, but also a feasible one.
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